Inducing Systemic Immunity and Regressions in Metastatic Melanoma

Metastatic Malignant Melanoma Clinical Trial

Official title: Inducing Systemic Immunity and Regressions in Metastatic Melanoma

Status Completed

Clinical Trial Summary

In patients with multiple metastatic nodules of melanoma, the investigators evaluated whether autologous cytokines injected into cutaneous metastases would induce a systemic immune response as evidenced by the accumulation of dense lymphocytic infiltrates in metastases that had never been injected. Such immune responses were observed, and often the never-injected metastasis regressed completely. 20% of patients remained free of disease for greater than 5 years.

Clinical Trial Description

Lymphocytic infiltrates were seen in never-injected nodules only after several weeks of injections elsewhere. No adverse events were seen. The tumor-infiltrating lymphocytes were able to kill autologous melanoma ex vivo. Some patients who experienced complete regressions of all metastases lived without disease for over 10 years. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Melanoma
• Metastatic Malignant Melanoma

• NCT number: NCT02350972
• Study type: Interventional
• Source: New York University School of Medicine
• Status: Completed
• Phase: Phase 1
• Start date: July 1978
• Completion date: May 2002